Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(2):94-95; doi:10.1093/jnci/95.2.94
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Young, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Young, R. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 2, 94-95, January 15, 2003
© 2003 Oxford University Press

EDITORIAL

Early-Stage Ovarian Cancer: To Treat or Not To Treat

Robert C. Young

Correspondence to: Robert C. Young, M.D., Fox Chase Cancer Center, 7701 Burholme Ave., Philadelphia, PA 19111 (RC_Young@fccc.edu).

The first 10% of the full text of this article appears below.

Approximately one-third of patients with epithelial ovarian cancer present with localized disease confined to the ovaries or pelvis (International Federation of Gynecology and Obstetrics [FIGO] stages I and II). Although their long-term prognosis is better (10-year survival = 50%–70%) than that of patients with advanced ovarian cancer (10-year survival = 15%–25%), approximately 50% of women with early-stage disease eventually relapse and succumb to their disease (1). These suboptimal survival results have led to major efforts to identify prognostic factors, improve surgical staging, and develop adjuvant therapies that could improve patient outcome. Earlier trials have been hampered by small size and limited statistical power and have not established a clear survival benefit for adjuvant treatment. Total abdominal irradiation and intraperitoneal . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
C. Trope and J. Kaern
Adjuvant Chemotherapy for Early-Stage Ovarian Cancer: Review of the Literature
J. Clin. Oncol., July 10, 2007; 25(20): 2909 - 2920.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J. Goodheart, J. M. Ritchie, S. L. Rose, J. P. Fruehauf, B. R. De Young, and R. E. Buller
The Relationship of Molecular Markers of p53 Function and Angiogenesis to Prognosis of Stage I Epithelial Ovarian Cancer
Clin. Cancer Res., May 15, 2005; 11(10): 3733 - 3742.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. A. Cannistra
Cancer of the Ovary
N. Engl. J. Med., December 9, 2004; 351(24): 2519 - 2529.
[Full Text] [PDF]

Home page
 JCOHome page
D. F. Kolomainen, R. A'Hern, F. Y. Coxon, C. Fisher, D. M. King, P. R. Blake, D. P.J. Barton, J. H. Shepherd, S. B. Kaye, and M. E. Gore
Can Patients With Relapsed, Previously Untreated, Stage I Epithelial Ovarian Cancer Be Successfully Treated With Salvage Therapy?
J. Clin. Oncol., August 15, 2003; 21(16): 3113 - 3118.
[Abstract] [Full Text] [PDF]

Home page
 JWatch GeneralHome page
Early-Stage Ovarian Cancer: Is Adjuvant Chemotherapy Warranted?
Journal Watch (General), February 7, 2003; 2003(207): 1 - 1.
[Full Text]